The results showed that HER2 status was significantly inconsistent between the primary breast cancer and metastases,37% exhibited heterogeneous HER2 expression between primary breast tumors and metastases, most of which changed from HER2 low expression to HER2–0 expression (34).Federica Miglietta et al. This evidence concerns the gene ERBB2 and breast carcinoma.